The exit of private equity from their investments in contract research organizations (CROs) could threaten its growth, says two financial experts at Partnerships in Clinical Trials.
Breaking News
The exit of private equity from their investments in contract research organizations (CROs) could threaten its growth, says two financial experts at Partnerships in Clinical Trials.
